{"id":"ffi-1010","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BTK is a key component of the B cell receptor signaling complex, and its inhibition has been shown to be effective in treating certain types of blood cancers. FFI-1010 works by selectively binding to and inhibiting the BTK enzyme, which can help to reduce the proliferation and survival of malignant B cells.","oneSentence":"FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:33.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory mantle cell lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT03345316","phase":"PHASE3","title":"Study of FFI-1010 in Pediatric Kidney Disease","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2017-11-01","conditions":"Children Under 18 Years Old With Kidney Disease","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FFI-1010","genericName":"FFI-1010","companyName":"Fuji Yakuhin Co., Ltd.","companyId":"fuji-yakuhin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}